Replies to post #222161 on Biotech Values

[rfj1862]

AMRN -11% on AHA presentation of REDUCE-IT; I presume this selloff will be relatively short-lived, but who knows?

It is a shame that Herper and Fuerstein published those articles; the more I read them the more frustrated I get. There really is no excuse for releasing such biased articles except to assuage egos and to be first. Even the excuse that Herper, in particular, was just interviewing KOLs doesn't fly--at the point these articles were published they didn't have time to really think about the data or dive into the details.

Each of the limitations suggested in these articles has been systematically addressed to my satisfaction. Will either of them publish follow-up articles presenting a more balanced view? I'm not going to hold my breath, both have way too much ego tied up in being right.

[Bickema]

AMRN - Dew do you have an opinion on the lack of a secondary following the initial climb into the 20's?